[Comparison of seasonal influenza vaccines: composition and properties].
Identifieur interne : 000260 ( Main/Corpus ); précédent : 000259; suivant : 000261[Comparison of seasonal influenza vaccines: composition and properties].
Auteurs : R. Allwinn ; H W DoerrSource :
- Deutsche medizinische Wochenschrift (1946) [ 1439-4413 ] ; 2011.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adolescent, Adult, Aged, Child, Child, Preschool, Germany, Humans, ISCOMs (adverse effects), ISCOMs (chemistry), ISCOMs (immunology), Infant, Influenza A virus (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (chemistry), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Liposomes, Mass Vaccination, Middle Aged, Vaccines, DNA (adverse effects), Vaccines, DNA (chemistry), Vaccines, DNA (immunology), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (chemistry), Vaccines, Inactivated (immunology), Vaccines, Subunit (adverse effects), Vaccines, Subunit (chemistry), Vaccines, Subunit (immunology), Vaccines, Virosome (adverse effects), Vaccines, Virosome (chemistry), Vaccines, Virosome (immunology), Virus Cultivation (methods), Young Adult.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic.
- chemical , adverse effects : ISCOMs, Influenza Vaccines, Vaccines, DNA, Vaccines, Inactivated, Vaccines, Subunit, Vaccines, Virosome.
- chemical , chemistry : ISCOMs, Influenza Vaccines, Vaccines, DNA, Vaccines, Inactivated, Vaccines, Subunit, Vaccines, Virosome.
- chemical , immunology : ISCOMs, Influenza Vaccines, Vaccines, DNA, Vaccines, Inactivated, Vaccines, Subunit, Vaccines, Virosome.
- geographic : Germany, Liposomes.
- immunology : Influenza A virus, Influenza, Human.
- methods : Virus Cultivation.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Humans, Infant, Mass Vaccination, Middle Aged, Young Adult.
Abstract
The influenza virus isolation in embryonated chicken eggs was possible early in 1930er years and allowed the influenza vaccine production. Most influenza vaccines were derived from this, but actually new virus cell culture methods are established. For better tolerability, influenza vaccines include only antigen proportions (split- and subunit vaccines) but with the disadvantage of minor vaccine efficacy. This was compared with the addition of adjuvants. Aluminium salts are used for many decades and still in use to enhance the effect of vaccines. New formulations are MF59, AS03, AS04 or toll- like receptor-agonists. Also virosomal formulations and "ISCOMs"(Immune Stimulating Complexes) are newly designed and compromises enhanced immune reactions. Actually a broad range of various influenza vaccines exist and are available for a very different group of patients (which depends on physical conditions, age, immune status or allergies).
DOI: 10.1055/s-0031-1292046
PubMed: 22048938
Links to Exploration step
pubmed:22048938Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Comparison of seasonal influenza vaccines: composition and properties].</title><author><name sortKey="Allwinn, R" sort="Allwinn, R" uniqKey="Allwinn R" first="R" last="Allwinn">R. Allwinn</name><affiliation><nlm:affiliation>Institut für Med. Virologie und Impfambulanz, Frankfurt/Main. allwinn@em.uni-frankfurt.de</nlm:affiliation></affiliation></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22048938</idno><idno type="pmid">22048938</idno><idno type="doi">10.1055/s-0031-1292046</idno><idno type="wicri:Area/Main/Corpus">000260</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Comparison of seasonal influenza vaccines: composition and properties].</title><author><name sortKey="Allwinn, R" sort="Allwinn, R" uniqKey="Allwinn R" first="R" last="Allwinn">R. Allwinn</name><affiliation><nlm:affiliation>Institut für Med. Virologie und Impfambulanz, Frankfurt/Main. allwinn@em.uni-frankfurt.de</nlm:affiliation></affiliation></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></analytic><series><title level="j">Deutsche medizinische Wochenschrift (1946)</title><idno type="eISSN">1439-4413</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Germany</term><term>Humans</term><term>ISCOMs (adverse effects)</term><term>ISCOMs (chemistry)</term><term>ISCOMs (immunology)</term><term>Infant</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (chemistry)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Liposomes</term><term>Mass Vaccination</term><term>Middle Aged</term><term>Vaccines, DNA (adverse effects)</term><term>Vaccines, DNA (chemistry)</term><term>Vaccines, DNA (immunology)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (chemistry)</term><term>Vaccines, Inactivated (immunology)</term><term>Vaccines, Subunit (adverse effects)</term><term>Vaccines, Subunit (chemistry)</term><term>Vaccines, Subunit (immunology)</term><term>Vaccines, Virosome (adverse effects)</term><term>Vaccines, Virosome (chemistry)</term><term>Vaccines, Virosome (immunology)</term><term>Virus Cultivation (methods)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>ISCOMs</term><term>Influenza Vaccines</term><term>Vaccines, DNA</term><term>Vaccines, Inactivated</term><term>Vaccines, Subunit</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>ISCOMs</term><term>Influenza Vaccines</term><term>Vaccines, DNA</term><term>Vaccines, Inactivated</term><term>Vaccines, Subunit</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>ISCOMs</term><term>Influenza Vaccines</term><term>Vaccines, DNA</term><term>Vaccines, Inactivated</term><term>Vaccines, Subunit</term><term>Vaccines, Virosome</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term><term>Liposomes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Virus Cultivation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Infant</term><term>Mass Vaccination</term><term>Middle Aged</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The influenza virus isolation in embryonated chicken eggs was possible early in 1930er years and allowed the influenza vaccine production. Most influenza vaccines were derived from this, but actually new virus cell culture methods are established. For better tolerability, influenza vaccines include only antigen proportions (split- and subunit vaccines) but with the disadvantage of minor vaccine efficacy. This was compared with the addition of adjuvants. Aluminium salts are used for many decades and still in use to enhance the effect of vaccines. New formulations are MF59, AS03, AS04 or toll- like receptor-agonists. Also virosomal formulations and "ISCOMs"(Immune Stimulating Complexes) are newly designed and compromises enhanced immune reactions. Actually a broad range of various influenza vaccines exist and are available for a very different group of patients (which depends on physical conditions, age, immune status or allergies).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22048938</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4413</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>45</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Deutsche medizinische Wochenschrift (1946)</Title><ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation></Journal><ArticleTitle>[Comparison of seasonal influenza vaccines: composition and properties].</ArticleTitle><Pagination><MedlinePgn>2315-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0031-1292046</ELocationID><Abstract><AbstractText>The influenza virus isolation in embryonated chicken eggs was possible early in 1930er years and allowed the influenza vaccine production. Most influenza vaccines were derived from this, but actually new virus cell culture methods are established. For better tolerability, influenza vaccines include only antigen proportions (split- and subunit vaccines) but with the disadvantage of minor vaccine efficacy. This was compared with the addition of adjuvants. Aluminium salts are used for many decades and still in use to enhance the effect of vaccines. New formulations are MF59, AS03, AS04 or toll- like receptor-agonists. Also virosomal formulations and "ISCOMs"(Immune Stimulating Complexes) are newly designed and compromises enhanced immune reactions. Actually a broad range of various influenza vaccines exist and are available for a very different group of patients (which depends on physical conditions, age, immune status or allergies).</AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allwinn</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut für Med. Virologie und Impfambulanz, Frankfurt/Main. allwinn@em.uni-frankfurt.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>H W</ForeName><Initials>HW</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Saisonale Influenza-Impfstoffe: Zusammensetzung und Eigenschaften.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Med Wochenschr</MedlineTA><NlmUniqueID>0006723</NlmUniqueID><ISSNLinking>0012-0472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016882">ISCOMs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022721">Vaccines, Virosome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016882" MajorTopicYN="N">ISCOMs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022721" MajorTopicYN="N">Vaccines, Virosome</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22048938</ArticleId><ArticleId IdType="doi">10.1055/s-0031-1292046</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:22048938
|texte= [Comparison of seasonal influenza vaccines: composition and properties].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:22048938" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |